Liu, Yunpeng

Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial

Qin, S., Chen, M., Cheng, A.-L., Kaseb, A. O., Kudo, M., Lee, H. C., Yopp, A. C., Zhou, J., Wang, L., Wen, X., et al. (2023) · The Lancet

Hepatocellular Carcinoma Treatment and PrognosisCancer Immunotherapy and Biomarkers

Cited by 545

Tislelizumab Plus Chemotherapy as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC (RATIONALE 304): A Randomized Phase 3 Trial

Lu, S., Wang, J., Yu, Y., Yu, X., Hu, Y., Ai, X., Ma, Z., Li, X., Zhuang, W., Liu, Y., et al. (2021) · Journal of Thoracic Oncology

Lung Cancer Treatments and MutationsCancer Immunotherapy and Biomarkers

Cited by 284

SARS‐CoV‐2 infection aggravates chronic comorbidities of cardiovascular diseases and diabetes in mice

Ma, Y., Lu, D., Bao, L., Qu, Y., Liu, J., Qi, X., Yu, L., Zhang, X., Qi, F., Lv, Q., et al. (2021) · Animal Models and Experimental Medicine

SARS-CoV-2 and COVID-19 ResearchCOVID-19 Clinical Research Studies

Cited by 25